SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 5.9  Revision Date: 09/13/2019  SDS Number: 58623-00016  Date of last issue: 2019/02/13
Date of first issue: 2015/02/16

1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Manufacturer or supplier's details
Company: MSD
Address: 199 Wenhai North Road
HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone: 908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

<table>
<thead>
<tr>
<th>Property</th>
<th>Classification/Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
</tbody>
</table>

May be harmful if swallowed. Causes mild skin irritation. Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life.

GHS Classification

<table>
<thead>
<tr>
<th>Property</th>
<th>Classification/Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute toxicity (Oral)</td>
<td>Category 5</td>
</tr>
<tr>
<td>Skin corrosion/irritation</td>
<td>Category 3</td>
</tr>
<tr>
<td>Serious eye damage/eye irritation</td>
<td>Category 2A</td>
</tr>
<tr>
<td>Reproductive toxicity</td>
<td>Category 2</td>
</tr>
<tr>
<td>Specific target organ toxicity - repeated exposure</td>
<td>Category 2</td>
</tr>
<tr>
<td>Short-term (acute) aquatic hazard</td>
<td>Category 3</td>
</tr>
</tbody>
</table>

GHS label elements
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Hazard pictograms : 
Signal word : Warning
Hazard statements : H303 May be harmful if swallowed.
H316 Causes mild skin irritation.
H319 Causes serious eye irritation.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs through prolonged or repeated exposure.
H402 Harmful to aquatic life.

Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P312 Call a POISON CENTER/doctor if you feel unwell.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
May be harmful if swallowed. Causes mild skin irritation. Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards
Harmful to aquatic life.
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 5.9
Revision Date: 09/13/2019
SDS Number: 58623-00016
Date of last issue: 2019/02/13
Date of first issue: 2015/02/16

Other hazards which do not result in classification
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 20 - &lt; 30</td>
</tr>
<tr>
<td></td>
<td>Lamivudine</td>
<td>134678-17-4</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td>Tenofovir</td>
<td>202138-50-9</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td>Doravirine</td>
<td>1338225-97-0</td>
<td>&gt;= 2.5 - &lt; 10</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.
In case of skin contact : In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed : May be harmful if swallowed. Causes mild skin irritation. Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
**SAFETY DATA SHEET**
according to GB/T 16483 and GB/T 17519

**Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.9</td>
<td>09/13/2019</td>
<td>58623-00016</td>
<td>2019/02/13</td>
<td>2015/02/16</td>
</tr>
</tbody>
</table>

**Unsuitable extinguishing media**: None known.

**Specific hazards during firefighting**: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

**Hazardous combustion products**: Carbon oxides
Nitrogen oxides (NOx)
Halogenated compounds

**Specific extinguishing methods**: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

**Special protective equipment for firefighters**: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

**Environmental precautions**: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

**Handling**

**Technical measures**: Static electricity may accumulate and ignite suspended dust causing an explosion.
SAFETY DATA SHEET
generated by GB/T 16483 and GB/T 17519

Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling:
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage:
Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>PC-TWA</td>
<td>10 mg/m3</td>
<td>GBZ 2.1-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>134678-17-4</td>
<td>TWA</td>
<td>150 µg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Tenofovir</td>
<td>202138-50-9</td>
<td>TWA</td>
<td>200 µg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Doravirine</td>
<td>1338225-97-0</td>
<td>TWA</td>
<td>500 µg/m3 (OEB2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-
Safety Data Sheet

Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 5.9  Revision Date: 09/13/2019  SDS Number: 58623-00016  Date of last issue: 2019/02/13

Date of first issue: 2015/02/16

Filter type: Particulates type
Eye/face protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.
Hand protection: Chemical-resistant gloves

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder
Colour: No data available
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks.
Avoid dust formation.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact
Acute toxicity
May be harmful if swallowed.

Product:
Acute oral toxicity : Acute toxicity estimate: 2,605 mg/kg
Method: Calculation method

Components:
Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Lamivudine:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): 4,000 mg/kg
Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg
Application Route: Intravenous

Tenofovir:
Acute oral toxicity : LD50 (Rat): > 1,500 mg/kg
LD50 (Dog): 30 mg/kg

Doravirine:
Acute oral toxicity : LD50 (Rat): > 750 mg/kg
Remarks: No mortality observed at this dose.

(Rat): Method: Phototoxicity
Remarks: No evidence of phototoxicity was observed
LD50 (Dog): > 1,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Mouse): > 450 mg/kg
Remarks: No mortality observed at this dose.

Skin corrosion/irritation
Causes mild skin irritation.
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Components:

Lamivudine:
Species : Rabbit
Result : Mild skin irritation

Tenofovir:
Species : Rabbit
Result : Mild skin irritation

Doravirine:
Remarks : No data available

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

Lamivudine:
Species : Rabbit
Result : No eye irritation

Tenofovir:
Species : Rabbit
Result : Severe irritation

Doravirine:
Remarks : No data available

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Lamivudine:
Exposure routes : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.

Tenofovir:
Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : Not a skin sensitizer.
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Doravirine:
Remarks : No data available

Germ cell mutagenicity
Not classified based on available information.

Components:

Cellulose:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Lamivudine:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mouse Lymphoma
Result: equivocal

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Application Route: Oral
Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Rat
Result: negative

Tenofovir:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: In vitro mammalian cell gene mutation test
Result: positive

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Germ cell mutagenicity - Assessment:

Weight of evidence does not support classification as a germ cell mutagen.

Doravirine:

Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Genotoxicity in vivo:
Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Carcinogenicity:

Not classified based on available information.

Components:

Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Lamivudine:
Species: Rat
Exposure time: 2 Years
Result: negative

Species: Mouse
Exposure time: 2 Years
Result: negative

Tenofovir:
Species: Mouse
Application Route: Oral
Exposure time: 104 weeks
Result: negative

Species: Rat
Application Route: Oral
Exposure time: 104 weeks
Result: negative
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Doravirine:
Species : Mouse
Application Route : Oral
Exposure time : 6 Months
Result : negative
Remarks : No significant adverse effects were reported

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Cellulose:
Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Lamivudine:
Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 900 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Symptoms: Preimplantation loss, Skeletal malformations
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 45 mg/kg body weight
Symptoms: Effects on foetal development
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Tenofovir:
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Effects on fertility:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Oral
- Result: No effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Oral
  - Result: No adverse effects
- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Result: No adverse effects

Doravirine:
Effects on fertility:
- Test Type: Fertility
- Species: Rat, male and female
- Fertility: NOAEL: 450 mg/kg body weight
- Result: No effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Oral
  - Developmental Toxicity: NOAEL: 450 mg/kg body weight
  - Result: No adverse effects
- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 300 mg/kg body weight
  - Result: No adverse effects

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Lamivudine:
- Exposure routes: Ingestion
- Target Organs: Blood
- Assessment: May cause damage to organs through prolonged or repeated exposure.

Tenofovir:
- Target Organs: Bone, Kidney
- Assessment: May cause damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

Components:

Cellulose:
Species: Rat
NOAEL: >= 9,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Lamivudine:
Species: Rat
NOAEL: 425 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Blood
Symptoms: Gastrointestinal discomfort, Breathing difficulties, Fatality
Remarks: Significant toxicity observed in testing

Species: Dog
LOAEL: 90 mg/kg
Application Route: Oral
Exposure time: 12 Months
Target Organs: Blood, spleen, Liver
Symptoms: Salivation, Diarrhoea, Changes in the blood count, Liver disorders, Gastrointestinal disturbance

Species: Mouse
NOAEL: 500 mg/kg
Application Route: Oral
Exposure time: 1 Months
Target Organs: Blood

Tenofovir:
Species: Rat
NOAEL: 30 mg/kg
LOAEL: 300 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Bone

Species: Dog
NOAEL: 3 mg/kg
LOAEL: >= 10 mg/kg
Application Route: Oral
Exposure time: 42 Weeks
Target Organs: Kidney

Species: Monkey
LOAEL: 10 mg/kg
Application Route: Subcutaneous
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Exposure time: 10 Months
Target Organs: Bone

Doravirine:
Species: Rat
NOAEL: 450 mg/kg
Application Route: Oral
Exposure time: 6 Months
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: > 450 mg/kg
Application Route: Oral
Exposure time: 3 Months
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: > 1,000 mg/kg
Application Route: Oral
Exposure time: 9 Months
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Lamivudine:
Ingestion: Symptoms: Headache, Fatigue, Respiratory disorders, Diarrhoea, Cough

Tenofovir:
Ingestion: Symptoms: Nausea, Diarrhoea, Vomiting, flatulence, Headache, Rash

Doravirine:
Ingestion: Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials
Lamivudine:
Toxicity to fish
: LC50 (Pimephales promelas (fathead minnow)): > 97.7 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates
: EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants
: EC50 (Pseudokirchneriella subcapitata (green algae)): > 96.9 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 96.9 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Tenofovir:
Toxicity to fish
: LC50 (Oncorhynchus mykiss (rainbow trout)): > 92 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates
: EC50 (Daphnia magna (Water flea)): > 98 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants
: EC50 (Pseudokirchneriella subcapitata (green algae)): 47 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 14 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity)
: NOEC (Pimephales promelas (fathead minnow)): 1.9 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
: NOEC (Daphnia magna (Water flea)): 13 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms
: EC50: 940 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

**NOEC**: 600 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**Doravirine:**

**Toxicity to daphnia and other aquatic invertebrates**

: EC50 (Daphnia magna (Water flea)): > 39 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): 9.1 mg/l
Exposure time: 96 h

**Toxicity to algae/aquatic plants**

: EC50 (Pseudokirchneriella subcapitata (green algae)): > 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 221
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 221
Remarks: No toxicity at the limit of solubility

**Toxicity to fish (Chronic toxicity)**

: NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**

: NOEC (Daphnia magna (Water flea)): 6.7 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

**Toxicity to microorganisms**

: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**Persistence and degradability**

**Components:**

**Cellulose:**

Biodegradability : Result: Readily biodegradable.
Lamivudine:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 4%
Exposure time: 28 d

Tenofovir:
Biodegradability: Result: Not readily biodegradable.

Doravirine:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 2%
Exposure time: 28 d

Bioaccumulative potential

Components:

Lamivudine:
Partition coefficient: n-octanol/water: log Pow: -1.44

Tenofovir:
Partition coefficient: n-octanol/water: log Pow: 1.18

Doravirine:
Partition coefficient: n-octanol/water: log Pow: 2.08

Mobility in soil

Components:

Lamivudine:
Distribution among environmental compartments: log Koc: 2.03

Tenofovir:
Distribution among environmental compartments: log Koc: 1.3

Doravirine:
Distribution among environmental compartments: log Koc: 2.86

Other adverse effects
No data available
13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations
GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information
Sources of key data used to compile the Safety Data : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 5.9  Revision Date: 09/13/2019  SDS Number: 58623-00016  Date of last issue: 2019/02/13
Date of first issue: 2015/02/16

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA : 8-hour, time-weighted average
GBZ 2.1-2007 / PC-TWA : Permissible concentration - time weighted average

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their
intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN